Forzinity, SS-31, Bendavia, MTP-131
Evidence Grade A — Regulatory approved. 183 published studies. 20 registered clinical trials.
Loading...
Elamipretide (sold as Forzinity) is the first treatment specifically approved for Barth syndrome, an ultra-rare genetic disorder that affects the energy-producing structures (mitochondria) in cells, causing muscle weakness, heart problems, and fatigue. Given as a daily injection, it is also the first mitochondria-targeted therapy to gain regulatory approval. Barth syndrome affects approximately 150 people in the US.
183 published studies: 82 human, 47 animal, 15 in-vitro, 47 reviews
Elamipretide (Forzinity) was approved by the FDA for Barth syndrome based on the TAZPOWER trial. The randomised crossover phase (12 patients) did not meet its primary endpoints, but the open-label extension (168 weeks) demonstrated durable improvements in walking distance and muscle strength that formed the basis for approval.
Barth syndrome affects approximately 1 in 300,000–400,000 births. A larger Phase III trial in primary mitochondrial myopathy (218 patients, MMPOWER-3) did not meet its primary endpoint, and the drug was not approved for that broader indication. Elamipretide remains approved exclusively for Barth syndrome. See also SS-31 (#158) for the research compound context.
Elamipretide selectively binds cardiolipin in the inner mitochondrial membrane, stabilising the membrane structures (cristae) that are essential for energy production. In Barth syndrome, a genetic defect causes cardiolipin abnormalities that disrupt mitochondrial energy production. Elamipretide directly addresses this structural defect, restoring mitochondrial function at its physical foundation.
Forzinity received FDA accelerated approval in September 2025 based on data from the TAZPOWER trial. The evidence is limited by the ultra-rare disease context — only 12 patients were enrolled in the randomised trial, which did not meet its primary endpoints for walking distance or fatigue scores. However, during the open-label extension period (where patients knew they were receiving the drug), improvements in knee extensor muscle strength were observed over 168 weeks. More than half of the original trial patients continue on treatment after more than eight years. The approval pathway was notable for its challenges: the initial application was refused, a second submission received a complete response rejection in May 2025, and a third submission targeting accelerated approval based on muscle strength was finally accepted in September 2025. A larger trial in primary mitochondrial myopathy (a more common condition) failed to meet its primary endpoint, and the drug was not approved for that broader use. Continued approval may depend on a confirmatory trial. Injection site reactions occur in virtually all patients.
An Intermediate Size Expanded Access Protocol of Elamipretide
Study of Healthy Aging and Physical Function With Elamipretide
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
FRDA Investigator Initiated Study (IIS) With Elamipretide
FDA ORIG 1
Exenatide was the first GLP-1 receptor agonist approved anywhere, reaching the market as Byetta in April 2005. The once-weekly formulation Bydureon followed in 2012. Clinical trials showed blood sugar reductions (HbA1c) of 1.6–1.9% and modest weight loss of 2–4 kg. The EXSCEL cardiovascular outcomes trial, involving over 14,700 patients, showed a trend toward cardiovascular benefit but narrowly missed statistical significance. While exenatide was groundbreaking as the first in its class, it has been largely overtaken by newer GLP-1 treatments that offer greater efficacy, less frequent dosing, and proven cardiovascular benefits. It remains available and in clinical use, particularly in combination products.
Lixisenatide was marketed as Adlyxin in the US (approved July 2016), though it has since been discontinued in the US market. The ELIXA cardiovascular trial, involving over 6,000 patients, was the first cardiovascular outcomes trial for any GLP-1 medication to report results. It showed a neutral cardiovascular profile — neither harmful nor beneficial — meeting safety requirements but not demonstrating the heart benefits later shown by semaglutide and liraglutide. Lixisenatide found its primary clinical role in combination with basal insulin, marketed as Soliqua (lixisenatide plus insulin glargine). This combination addresses both fasting blood sugar (via insulin) and post-meal spikes (via lixisenatide) in a single daily injection. As a standalone treatment, it has been largely superseded by more potent GLP-1 medications.
Pramlintide is marketed as Symlin (approved March 2005) and remains the only approved amylin-based treatment. It is used alongside mealtime insulin in both type 1 and type 2 diabetes. Clinical trials showed modest blood sugar improvements (HbA1c reductions of 0.2–0.6%) and approximately 2.3 kg of weight loss — less dramatic than GLP-1 treatments but meaningful as an add-on therapy. Symlin carries a boxed warning for severe hypoglycaemia, particularly when combined with insulin, and requires careful dose adjustment. Practical uptake has been limited by the need for separate injections at each meal alongside existing insulin injections. Despite its modest clinical impact, pramlintide remains the only medication that addresses the amylin deficiency in diabetes, filling a distinct biological role that GLP-1 treatments do not cover.
